Homology Medicines is on a mission to advance our proprietary gene editing and gene therapy platform and transform the lives of patients by potentially curing rare genetic diseases.
Our Company is based on an important scientific discovery – a novel set of adeno-associated virus vectors derived from human hematopoietic stem cells (AAVHSCs) that are designed to precisely and efficiently deliver genetic medicines in vivo either through gene therapy or by harnessing the body’s natural DNA repair process of homologous recombination through nuclease-free gene editing.
Our technology platform offers substantial benefits over current gene editing and gene therapy approaches and could potentially enable the development of one-time curative treatments.
View our corporate profile.
Homology Medicines has brought together a team of experienced and dedicated leaders in rare diseases and genetic medicines to translate our technology platform into treatments for patients